“Long-Term Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks in Patients With Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S36. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/763.